36-008
Anti-α-Synuclein (SNCA) Antibody
UPSTATE®, mouse monoclonal, Syn211
Synonim(y):
Anti-NACP, Anti-PARK1, Anti-PARK4, Anti-PD1
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
Informacje o tej pozycji
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Clone:
Syn211, monoclonal
Species reactivity:
human
Application:
IHC, IP, WB
Citations:
29
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócNazwa produktu
Anti-α-Synuclein Antibody, clone Syn211, ascites fluid, clone Syn211, Upstate®
biological source
mouse
Quality Level
antibody form
ascites fluid
antibody product type
primary antibodies
clone
Syn211, monoclonal
species reactivity
human
packaging
antibody small pack of 25 μL
manufacturer/tradename
Upstate®
technique(s)
immunohistochemistry: suitable, immunoprecipitation (IP): suitable, western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
ambient
target post-translational modification
unmodified
Gene Information
human ... SNCA(6622)
General description
~14.5kDa
Immunogen
full-length recombinant human α-Synuclein
Application
Detect α-Synuclein using this Anti-α-Synuclein Antibody, clone Syn211 validated for use in IP, WB, IH.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Biochem/physiol Actions
α-Synuclein
Physical form
Ascites
Preparation Note
2 years at -20°C
Analysis Note
Routinely evaluated by immunoblot on Alzheimer′s diseased human whole brain lysates.
Other Notes
Replaces: 04-1053
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ta strona może zawierać tekst przetłumaczony maszynowo.
Still not finding the right product?
Klasa składowania
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Powiązane treści
Jay S Schneider et al.
Molecular and cellular neurosciences, 120, 103729-103729 (2022-04-22)
Among the pathological events associated with the dopaminergic neurodegeneration characteristic of Parkinson's disease (PD) are the accumulation of toxic forms of α-synuclein and microglial activation associated with neuroinflammation. Although numerous other processes may participate in the pathogenesis of PD, the
Sarah M O'Donovan et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 32(1), e13726-e13726 (2019-10-03)
A hallmark feature of Parkinson's disease (PD) is the build-up of α-synuclein protein aggregates throughout the brain; however α-synuclein is also expressed in enteric neurons. Gastrointestinal (GI) symptoms and pathology are frequently reported in PD, including constipation, increased intestinal permeability
Rachel Kelly et al.
Molecules (Basel, Switzerland), 27(2) (2022-01-22)
Since the discovery of α-synuclein as the major component in Lewy bodies, research into this protein in the context of Parkinson's disease pathology has been exponential. Cannabinoids are being investigated as potential therapies for Parkinson's disease from numerous aspects, but
Numer pozycji handlu globalnego
| SKU | NUMER GTIN |
|---|---|
| 36-008-25UL | 04054839337352 |